Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$129.61M-27.0%-$127.41M-46.4%-$142.46M-136%-$133.56M-109%-$102.02M-24.1%
$31K-88.0%$26K-90.8%$25K-91.7%$231K+112%$258K+150%
$24.99M+230%$20.01M+114%$11.87M+4.6%$7.6M-47.8%$7.57M-44.8%
-$100.01M-108%-$94.69M-78.4%-$83.65M-84.8%-$68.33M-26.3%-$48.17M+30.2%
$196K
-$268.33M-1,133%-$247.01M-1,225%-$135.72M-1,037%$12.99M$25.98M
$360.67M+93.8%$360.77M+92.7%$282.61M+195%$377.38M+39,458%$186.07M+302%
$5.16M-96.3%$19.05M-86.7%$50.11M$308.91M$137.9M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Jade Biosciences, Inc. Common Stock generate?
Jade Biosciences, Inc. Common Stock (JBIO) generated -$100.0M in operating cash flow over the trailing twelve months.
What is Jade Biosciences, Inc. Common Stock's free cash flow?
After $196.0K of capital expenditures, Jade Biosciences, Inc. Common Stock's free cash flow was -$94.9M over the trailing twelve months, down 66.7% year over year.
Where does Jade Biosciences, Inc. Common Stock's cash flow data come from?
Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.